Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Authors :: Chevallier P
Chantepie S
Huguet F
Raffoux E
Thomas X
Leguay T
Marchand T
Isnard F
Charbonnier A
Maury S
Gallego-Hernanz MP
Robillard N
Guillaume T
Peterlin P
Garnier A
Rialland F
Le Houerou C
Goldenberg DM
Wegener WA
Béné MC
Dombret H
Source :: Haematologica [Haematologica] 2017 May; Vol. 102 (5), pp. e184-e186. Date of Electronic Publication: 2017 Feb 02.
Publication Year :: 2017

Subjects :: Adult
Antibodies, Monoclonal, Humanized administration & dosage
Antineoplastic Combined Chemotherapy Protocols adverse effects
Biomarkers
Cyclophosphamide adverse effects
Cyclophosphamide therapeutic use
Dexamethasone adverse effects
Dexamethasone therapeutic use
Doxorubicin adverse effects
Doxorubicin therapeutic use
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma mortality
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology
Recurrence
Retreatment
Treatment Outcome
Vincristine adverse effects
Vincristine therapeutic use
Young Adult
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism
Sialic Acid Binding Ig-like Lectin 2 metabolism

Full Text Access

Tools